Skip to main navigation
Skip to search
Skip to main content
Technical University of Munich Home
Help & FAQ
Link opens in a new tab
English
Deutsch
Search content at Technical University of Munich
Home
Profiles
Research units
Projects
Research output
Equipment
Prizes
Activities
Press/Media
Neues zur therapie der mastozytose
Translated title of the contribution
:
New therapeutic developments for mastocytosis
K. Brockow
, M. Grosber
, K. Hölzle
, H. Behrendt
,
J. Ring
TUM Emeriti of Excellence
Department of Dermatology and Allergology
Technical University of Munich
Research output
:
Contribution to journal
›
Review article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New therapeutic developments for mastocytosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adult Patients
12%
Anaphylaxis
37%
Anti-IgE Antibody
12%
Antineoplastic Drugs
12%
Cell number
12%
Curative Treatment
12%
Cutaneous Mastocytosis
25%
Cytostatic Drugs
25%
General Anesthesia
12%
Histamine
12%
Inappropriate Treatment
12%
Inhibitor Drug
12%
Insect Venom
12%
Mast Cell Mediators
12%
Mast Cells
12%
Mastocytosis
100%
Mild Disease
12%
New Therapeutic Approaches
12%
New Therapeutics
100%
Omalizumab
12%
Patients at Risk
12%
Precautionary Measures
12%
Recurrent Anaphylaxis
12%
Response Rate
12%
Self-medication
12%
Specific Immunotherapy
12%
Therapeutic Development
100%
Topical Therapy
25%
Treatment Modalities
12%
Tyrosine Kinase Inhibitor
25%
Medicine and Dentistry
Anaphylaxis
50%
Cytostatic Agent
25%
Diseases
37%
General Anesthesia
12%
Histamine
12%
Immunoglobulin E Antibody
12%
Immunotherapy
12%
Insect Venom
12%
Mast Cell
25%
Mastocytosis
100%
Mediator
12%
Omalizumab
12%
Self-Medication
12%
Topical Treatment
25%
Treatment Modality
12%
Tyrosine-Kinase Inhibitor
25%
Urticaria Pigmentosa
25%
Pharmacology, Toxicology and Pharmaceutical Science
Anaphylaxis
50%
Cytostatic Agent
25%
Diseases
37%
Histamine
12%
Immunoglobulin E Antibody
12%
Immunotherapy
12%
Insect Toxin
12%
Mastocytosis
100%
Omalizumab
12%
Protein Tyrosine Kinase Inhibitor
25%
Self-Medication
12%
Urticaria Pigmentosa
25%